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Previewsactivated during lineage development
from gut endoderm.
In their shRNA gene suppression
experiment, reducing FOXA1 expression
by 50%, the authors also analyzed the
enrichment for the H3K4me1 mark at six
selected enhancers and found no differ-
ence compared to controlled cells. They
suggest that FOXA1might not be involved
directly in establishing this mark. While
this is of course possible, the data on
this point are not definitive, as genetic ex-
periments have shown partial redundancy
among the Foxa factors in multiple in-
stances (Gao et al., 2008; Li et al.,
2009; Wan et al., 2005). Thus, it is likely
that a 50% reduction in FOXA1 levels as
achieved by the authors is compensated
in part by continued presence of FOXA2
and FOXA3. Therefore, it remains to be
seen if these FOXA bound enhancers
can be established during hESC differen-
tiation without any FOXA protein present.
In summary, the comprehensive study
by Wang and colleagues demonstrates344 Cell Stem Cell 16, April 2, 2015 ª2015 Elthat the establishment of developmental
competence during hESC differentiation
toward the endoderm-derived organs oc-
curs in a stepwisemanner, with entire sets
of enhancers first poised and then acti-
vated depending on which lineage is tar-
geted. In addition, these enhancers are
first occupied by the winged helix tran-
scription factors FOXA1 and FOXA2
during the acquisition of developmental
competence, while lineage-specific tran-
scription factors are recruited at subse-
quent steps. These findings suggest that
effective reprogramming of somatic cells
might require both the action of pioneer
factors, such as the FOXA proteins, and
lineage-specific transcription factors for
full activation of the transcriptome appro-
priate for a given lineage.
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Long noncoding RNAs (lncRNAs) influence diverse cellular processes and have been implicated in regulating
stem cell properties. Now in Cell Stem Cell, Ramos et al. (2015) demonstrate that the neural-specific lncRNA
Pnky regulates neuronal differentiation from neural stem cells and mediates RNA splicing through interac-
tions with polypyrimidine tract-binding protein 1 (PTBP1).lncRNAs are noncoding transcripts that
are increasingly appreciated as important
regulators of cellular function. They are
greater than 200 nucleotides in length
and, similar to protein-coding transcripts,
undergo capping, polyadenylation, and
splicing. lncRNAs are often expressed in
a highly cell type-dependent or tissue-
specific manner, but they exhibit lower
conservation at the sequence level com-
pared to protein-coding RNAs (Batistaand Chang, 2013). While previously
considered as transcriptional junk, recent
evidence suggests that lncRNAs par-
ticipate in many cellular regulatory pro-
cesses including X chromosome inactiva-
tion, epigenetic chromatin modification,
RNA processing, and transcriptional and
post-transcriptional control of gene ex-
pression (Batista and Chang, 2013).
Importantly, recent studies have demon-
strated that lncRNAs are crucial playersin the pluripotency network. The lncRNAs
Gomafu (AK028326) and AK141205 are
involved in the maintenance of pluripo-
tency in mouse embryonic stem cells
(mESCs) (Sheik Mohamed et al., 2010),
while others, for instanceMistral, promote
mESC differentiation (Bertani et al., 2011).
Now in Cell Stem Cell, Ramos et al. (2015)
demonstrate that the lncRNA Pnky re-
gulates differentiation of embryonic and
postnatal neural stem cells (NSCs).
Cell Stem Cell
PreviewsIn contrast to their demonstrated roles
in regulating pluripotent stem cells, only
a few annotated lncRNAs have been
implicated in brain development. For
instance, rhabdomyosarcoma 2-associ-
ated transcript (RMST) is required for
dopaminergic neuron differentiation (Ng
et al., 2013). Tcl1 upstream neuron-asso-
ciated lncRNA (TUNA) also promotes
neurogenesis by forming a complex with
RNA-binding proteins (Lin et al., 2014).
In a previous analysis, the authors identi-
fied several lncRNAs enriched in the adult
ventricular-subventricular zone (V-SVZ) of
themammalian brain (Ramos et al., 2013).
Several of these lncRNAs were demon-
strated to regulate neural fate specifica-
tion, suggesting that other identified can-
didates, such as Pnky, may also control
neurogenesis.
Ramos et al. (2015) now perform in-
depth analyses of Pnky in the brain.
In mESCs, the Pnky promoter dis-
played a bivalent methylation pattern
with H3K4me3 and H3K27me3 marks,
indicating that it is poised for expression,
which resolved to an active H3K4me3
pattern in V-SVZ-derived NSCs. Pnky ex-
pression was confirmed in V-SVZ NSCs
by fluorescent activated cell sorting
(FACS) and analysis of adult brain tissue
sections, implying that it may function in
regulating cell fate decisions.
The authors then asked whether Pnky
mediates such decisions. Knocking down
Pnky expression in vitro resulted in
increased neuronal production without
affecting NSC proliferation. Rather, this
effect was due to increased divisions
of a downstream transit-amplifying pro-
genitor population. Time-lapse imaging
of real-time cellular behavior after Pnky
manipulation further demonstrated that
Pnky knockdown promoted neuronal fate
choice, proliferation of neuronal progeni-
tors, and reductionof cell death. To assess
the function of Pnky during embryonic
brain development, the authors performed
in utero electroporation to knock down
Pnky expression. They found that although
Pnky was expressed similarly and likewise
functioned in controlling neuronal differen-
tiation, as in the postnatal brain, Pnky
knockdown in embryonic stages depletedNSCs without changing proliferation of
transit-amplifying neuronal progenitors or
cell death, suggesting that it may directly
promotedifferentiation. These results sug-
gest that thedevelopmental stage, in addi-
tion to the cell type- or tissue-specificity
of lncRNAs, may be an important feature
in uncovering lncRNA function. An inter-
esting follow-up question is howPnky pro-
motes neurogenesis in such a develop-
mental stage-dependent manner.
To address this issue, Ramos and
colleagues performed in vitro binding as-
says and incubated biotinylated Pnky
RNAs with V-SVZ lysates to identify inter-
acting proteins by mass spectrometry.
Through this analysis, the authors found
that polypyrimidine tract-binding pro-
tein 1 (PTBP1), an RNA-binding protein
known to suppress neuronal differentia-
tion (Makeyev et al., 2007), could bind
to the Pnky transcript. Similar to Pnky
knockdown, PTBP1 knockdown also pro-
moted neurogenesis. However, a PTBP1
downstream molecule, PTBP2, did not
bind to Pnky, and PTBP2 expression
was slightly reduced by Pnky knockdown.
PTBP1 is well-known to regulate mRNA
splicing during neuronal differentiation,
and Ramos et al. next evaluated whether
Pnky and PTBP1 function in the same
pathway. Knockdown of either gene re-
sulted in alternate splicing of similar tran-
scripts, suggesting that they may act
together to regulate neurogenesis. Con-
sistently, in an epistasis experiment, dou-
ble knockdown of Pnky and PTBP1 did
not show an additive effect on the expres-
sion level of representative genes per-
turbed by single manipulation of Pnky or
PTBP1. Taken together, the results of
Ramos et al. show that Pnky functions to
control RNA splicing, thereby influencing
neuronal differentiation of NSCs.
Based on the discovery of the regulato-
ry lncRNA Pnky and its binding partner, a
next important step will be to examine the
functional impact of Pnky manipulation in
disease. Because SVZ NSCs generate
new neurons that migrate to damaged
brain areas, possibly for the replacement
of damaged neurons after stroke (Kernie
and Parent, 2010), Pnky knockdown may
have therapeutic potential in treating brainCell Stem Ceischemia by promoting neural progenitor
proliferation and reducing cell death. On
the other hand, since SVZ NSCs might
be a source of brain tumors, maintenance
or upregulation of Pnky may suppress
self-renewal of SVZ NSCs, thus inter-
fering with tumorigenesis. This is further
supported by the report showing that
PTBP1 differentially splices fibroblast
growth factor receptor-1 (FGFR-1), mak-
ing it a high-affinity receptor form that
is frequently detected in glioblastoma
(Jin et al., 2000). Emerging data also
suggest that lncRNAs are associated
with the pathophysiology of various neu-
rological diseases including Alzheimer
disease, schizophrenia, Huntington dis-
ease, depression, autism spectrum disor-
der, and Angelman syndrome (Ng et al.,
2013), and understanding Pnky expres-
sion in these contexts may prove useful
as well. Together, these findings provide
a foundation for linking neural-specific
lncRNAs to human diseases, opening
possible avenues for future therapies.REFERENCES
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